Important Safety Information
Online SamplingASTRAZENECA PRIVACY STATEMENT
LAST UPDATED: July 08, 2008
- Introduction
- Collection of Information
- Security
- Cookies
- Advertising
- Minors
- Tell A Friend
- Links
- Contact Us
Introduction
AstraZeneca respects that the privacy of your personal information is important to you. We have developed this privacy statement to let you know how the Information (as defined below) that we collect about you will be maintained and used. We may change this statement from time to time so we ask that you revisit this privacy statement to be sure that you are familiar with our current policies because the revised policy will apply to you. In the event we make any changes to this privacy statement we will post the revised policy on this web site together with the date on which we made the most recent changes.
If you are a physician or other health care professional, this statement only applies to Information collected online through this web site, other AstraZeneca web sites, or where we specifically say that this policy shall apply.
Collection of Information
AstraZeneca may collect personally identifiable information about you, such as name, address, telephone number, e-mail address, date of birth, or other similar information ("Information") when you voluntarily submit it to us or when you give permission to others to share such Information with us. Your Information may be used to fulfill your request for information, to send you health-related materials, to develop products, services and programs that you may find useful, to provide access to your account information, or to contact you. If you do provide Information to us, you agree that we may contact you through a variety of methods including postal mail, e-mail and telephone. From time to time we may also request that you provide us with additional demographic, or other health information through responses to questions or surveys, or through use of search functions or other forms of feedback that we may use to serve you better. Except as specifically provided in this privacy statement, AstraZeneca will not transfer, sell or rent Information to anyone without your consent. We may share your information with other AstraZeneca companies worldwide or with our co-promotion partners. We may occasionally transfer or share your Information with third parties who perform certain services on our behalf. Such third parties have agreed that they will only use the Information on behalf of AstraZeneca. All Information that we transfer or share will be used and disclosed in a manner consistent with the terms of this privacy statement.
You can visit much of our web site without providing us with Information. However, some areas of the web site may require that you register in order to access specific content, features, interactive tools, or services or participate in a particular activity, such as subscribing to a newsletter or joining a program. You may always choose not to provide the requested Information but you may then not be able to participate in the particular activity.
Through our web sites, AstraZeneca also collects non-personally identifiable information relating to such matters as: the total number of visits to our web sites, the number of visitors to each page of our web sites, the Internet Protocol (IP) addresses of our visitors, and the time spent on our web sites. We use this information to understand how our visitors use our web sites so we can improve the customer experience. We may also use your IP address to help diagnose problems with our servers, and for purposes of system administration. From time to time we may also share non-personally identifiable information with others.
We gather aggregate data about visitors to our web sites for purposes of product development and improvement of our web sites, and also for market analysis. We may provide information from our web sites in aggregate form without personally identifiable information to third parties. Any third party that receives aggregated data must agree not to attempt to re-identify the persons to whom it belongs.
If you contact us to report on your experience, or the experiences of your patient, with the use of our products, we may contact you for follow up information. We may also use the information you provide to submit reports of side effects to government agencies such as the U.S. Food and Drug Administration, or as otherwise required by law or governmental audit.
AstraZeneca reserves the right to share your Information in order to respond to authorized information requests of government authorities, the courts, law enforcement agencies or where required by law, or for corporate audits or to respond to complaints or security threats. Further, in the event we determine for business reasons to reorganize, sell or transfer a product or all or a part of our business, we may share your Information with third parties involved in such transactions, such as actual or prospective purchasers, and other business partners, in which case we will obtain written assurances that the Information will be appropriately protected.
Security
AstraZeneca uses reasonable technical and administrative safeguards to protect Information from unauthorized access, use, loss or destruction. Any Information you provide to us is held on a secured web server (a computer that stores web documents, allowing users to access web pages using web client software) operated by AstraZeneca (or by an agent of AstraZeneca performing services on our behalf). Please be advised that although we have tried to create a secured and reliable site for you, the confidentiality of any Information, or communication or material transmitted over the Internet cannot be guaranteed. We urge you to exercise caution when conveying personally identifiable information over the Internet. When disclosing any personally identifiable information, you should remain mindful that such information might be accessible by the public and, consequently, may be collected and used by others without your consent. You should also recognize that your use of the Internet and this site is solely at your own risk.
Cookies
The use of cookies is now standard, and you will find them used by most major web sites. A cookie is a text file stored on a user's computer hard drive containing information about the user. Cookies are used for a variety of purposes, including to help you log into parts of our web sites, to enable us to track the interests of our users to enhance their experience on this site, for market research purposes, and to deliver content specific to a user's interests. We will place a cookie in the web browser (e.g., Internet Explorer) file of your computer when you visit our site; we or an independent advertising company or other contractor whom we engage may also from time to time deliver a uniquely-numbered cookie to your web browser through an e-mail if you have opted-in to receive e-mail from AstraZeneca. You may delete or decline the cookie using the tools in your web browser, and you may still use our site; however, some parts of our site may not work properly for you.
Advertising
We sometimes use independent advertising companies to provide ads on our behalf across the Internet ("advertising company"). These advertising companies also help us analyze our advertising campaigns and the general usage patterns of visitors to our web sites. This is primarily accomplished through the use of cookies, and Internet tags (such as action tags, web beacons, pixel tags, clear GIF (Graphics Interchange Format) images and invisible GIFs). Such companies may place these tags on our web sites or on other web sites. Used in conjunction with cookies, Internet tags are programmed by the advertising company to collect certain non-personally identifiable information about visitors to our web site and other web sites. This information may be used to provide ads about goods and services of potential interest to you, or to improve your web site experience. The advertising company does not know the names, addresses, e-mail addresses or telephone numbers of web site visitors, and does not link online actions to an identifiable person. The advertising company reports the non-identifiable data that it collects on our behalf back to us without identifying specific web site visits (other than to our own Web sites). We use this information to improve our web sites and our advertising. In order to deliver more relevant content or advertising, from time to time we may link the information we receive to our customers' Information. If we do link such data, it is treated under this policy as Information as described above under Collection of Information. If you would like more information about this practice, or if you want to prevent an independent advertising company from sending and reading cookies or action tags on your computer, you can visit the advertising company's web site and opt out.
Minors
We do not knowingly collect directly any personal information from anyone under the age of 13, nor do we knowingly market our web sites to anyone under the age of 13.
Tell-A-Friend
On some AstraZeneca sites, you can choose to use a "tell-a-friend" or referral function on our website to let someone else know about an AstraZeneca web site or product. In such a case we will ask for your friend's name and email address, as well as Information about you. The information that you may provide for a friend will be used to send an email on your behalf and will not be collected or stored by AstraZeneca for any additional purpose.
Links
As a convenience to you, AstraZeneca may provide links from this web site to other web sites maintained by independent third parties. This privacy statement applies solely to the information collected on this web site. We are not responsible for the privacy practices of such other sites. We encourage you to be aware when you leave this site and to read the privacy policies of any web site that you may visit.
Contact Us
We welcome your questions and comments regarding this privacy statement and the use of your Information. You may also contact us to update or correct the Information you have provided to us or to opt out of services that you may have previously signed up for. If you have any questions about this privacy statement or about our use of Information, or if you would like to request any changes be made to your Information, please contact the Information Center at AstraZeneca at 800-236-9933.
Important Safety Information for CRESTOR Tablets
- CRESTOR is contraindicated in patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers
- Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with statins, including CRESTOR. These risks can occur at any dose level but are increased at the highest dose (40 mg)
- CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age ≥65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, lopinavir/ritonavir, or atazanavir/ritonavir
- Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever
- It is recommended that liver enzyme tests be performed before the initiation of CRESTOR and if signs or symptoms of liver injury occur. All patients treated with CRESTOR should be advised to promptly report any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including CRESTOR. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with CRESTOR, promptly interrupt therapy. If an alternate etiology is not found, do not restart CRESTOR
- CRESTOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of chronic liver disease
- CRESTOR significantly increased INR in patients receiving coumarin anticoagulants. In patients taking coumarin anticoagulants and CRESTOR concomitantly, INR should be determined before starting CRESTOR and frequently enough during early therapy to ensure that no significant alteration of INR occurs
- Dipstick-positive proteinuria and microscopic hematuria were observed among patients treated with CRESTOR. These findings were more frequent in patients taking CRESTOR 40 mg, though it was generally transient and was not associated with worsening renal function. Although the clinical significance of this finding is unknown, dose reduction should be considered for patients on CRESTOR therapy with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing
- Increases in HbA1c and fasting serum glucose levels have been reported with statins, including CRESTOR
- In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%)#‡‡
- Rare postmarketing reports of cognitive impairment (eg, memory loss, forgetfulness, amnesia, memory impairment, confusion) have been associated with statin use, including CRESTOR. These reports are generally nonserious and reversible upon statin discontinuation
- The dose range for CRESTOR is 5 mg to 40 mg orally once daily. The usual starting dose is 10 mg to 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose. After initiation or upon titration of CRESTOR, lipid levels should be analyzed within 2 to 4 weeks and the dosage adjusted accordingly. CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg
Indications
- CRESTOR is indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides, and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia and to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels
- CRESTOR is indicated to reduce the risk of myocardial infarction, stroke, and arterial revascularization procedures in patients without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) based on age (men ≥50 and women ≥60), high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and the presence of at least one additional CVD risk factor, such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease
Read full Prescribing Information 
(PDF - 152k) 
Please see the full Prescribing Information available at CrestorTouchPoints.com
CRESTOR is licensed from SHIONOGI & CO, LTD, Osaka, Japan.
CRESTOR is a registered trademark of the AstraZeneca group of companies.
©2012 AstraZeneca. All rights reserved. 1569505 3
This product information is intended for US health care professionals only.
